Does it work for a double chin or a less-defined jawline?
A double chin or softness along the jawline is one of the concerns InMode RF Lifting handles particularly well. Because it delivers heat to the fat layer while also working to tighten the skin, it's often considered by patients bothered by fullness in this area.
Designed to Work Directly on Fat
That line under the chin you notice when you take off your mask — it can be hard to ignore. Fullness under the chin and along the cheeks is often the result of two things overlapping: how fat sits in the area and laxity in the skin. InMode RF Lifting delivers deep heat at 45–47°C to act on fat cells while also aiming to tighten the dermis and SMAS layer, which is why it's a frequent choice for patients concerned about a fat-related double chin. At our clinic, we offer it as a treatment aimed at improving sagging cheeks and a double chin.
Rather than a dramatic change immediately after treatment, most patients notice their jawline looking different over a period of days to weeks. Since results vary from person to person, we follow up over time to track your progress.
Suitability Depends on the Underlying Cause
On the other hand, if the fullness is mainly due to excess skin, bone structure, or age-related tissue descent, InMode RF Lifting on its own may not get you as close to the change you're hoping for. It may also not be the right fit for those with hollow cheeks or minimal fat, since a fat-reducing treatment can work against you in those cases.
Examining how your face looks in profile and when you look down helps us determine whether this treatment suits your facial contours. During your consultation at PGC Clinic Shinjuku, please tell us which areas you'd like to slim down and which you'd like to keep — we'd love to hear it.
This content is general information; results and recovery vary from person to person. All treatments at our clinic are self-paid (not covered by public insurance). Where a treatment uses pharmaceuticals or devices not yet approved in Japan, details are provided on our Global Drug Advisory page.